(Total Views: 487)
Posted On: 09/18/2019 7:31:18 PM
Post# of 155372
“So personally I think different . Globally COPD is in about 25 Bill a year market ....”
The yearly market of an indication is not relevant to the market cap of CYDY. How do I know? Because CYDY is still valued at $150 million despite nearing approval for HIV and having very promising results in cancer. The cancer patient on Leronlimab could be cured of her disease and grow wings, but no one would ever notice.
NP hasn’t got the message either. For awhile he kept saying how phase 2 NASH biotechs have at least a billion dollar market cap. Sure, THOSE biotechs do, but they’re not CYDY, stuck on the OTC with dilutive financing lining up at the door to water down investors.
The yearly market of an indication is not relevant to the market cap of CYDY. How do I know? Because CYDY is still valued at $150 million despite nearing approval for HIV and having very promising results in cancer. The cancer patient on Leronlimab could be cured of her disease and grow wings, but no one would ever notice.
NP hasn’t got the message either. For awhile he kept saying how phase 2 NASH biotechs have at least a billion dollar market cap. Sure, THOSE biotechs do, but they’re not CYDY, stuck on the OTC with dilutive financing lining up at the door to water down investors.
(1)
(0)
